menu

Bridge to Understanding: Your Connection to Advancements in Psoriasis and PsA Treatments

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Bridge to Understanding: Your Connection to Advancements in Psoriasis and PsA Treatments

0.75 credits
45 Minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.

  • Disclosure of Conflicts of Interest

    Disclosure and Conflict of Interest Resolution

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with ineligible company(ies)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be an ineligible company – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 24 months, financial relationship(s) with ineligible companies relative to the content of this CME activity:

    • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD; Megan Ragan

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    • Faculty Presenter: April W. Armstrong, MD, MPH
      • Consultant: AbbVie, Almirall, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Janssen, Leo, Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharmaceuticals, UCB
    • Faculty Presenter: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      • Consultant: AbbVie, Amgen, Novartis, Pfizer
      • Advisor: AbbVie, Amgen, Pfizer
      • Speaker: AbbVie, Amgen, Lilly, Pfizer
      • Ownership interest: AbbVie, Amgen, Johnson & Johnson, Pfizer, Regeneron

  • Target Audience

    The primary target audiences are dermatologists and nurse practitioners and physician assistants who specialize in dermatology. Rheumatology providers and other clinicians who treat patients with psoriasis or PsA may benefit from participation in this activity.

  • Learning Objectives

    As a result of participation in this activity, participants should increase their ability to:

    1. Apply evidence-based clinical practice guideline recommendations to improve management of psoriatic disease and treatment outcomes.
    2. Summarize the results of key clinical trials for novel and emerging therapies intended to improve symptoms, and slow or prevent progression of psoriasis and PsA.
    3. Optimize individual treatment plans for psoriatic disease in the context of patient-provider shared decision making.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty, and do not necessarily reflect the views or recommendations of Forefront Collaborative and AbbVie.

    The content of this activity was independently peer reviewed by two reviewers and a patient with psoriasis and psoriatic arthritis. The reviewers of this activity had no relevant financial relationships to disclose.

    This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational grant from AbbVie. For further information concerning AbbVie grant funding, visit www.abbvie.com/grants

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.

  • Disclosure of Conflicts of Interest

    Disclosure and Conflict of Interest Resolution

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with ineligible company(ies)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be an ineligible company – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 24 months, financial relationship(s) with ineligible companies relative to the content of this CME activity:

    • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD; Megan Ragan

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    • Faculty Presenter: April W. Armstrong, MD, MPH
      • Consultant: AbbVie, Almirall, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Janssen, Leo, Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharmaceuticals, UCB
    • Faculty Presenter: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      • Consultant: AbbVie, Amgen, Novartis, Pfizer
      • Advisor: AbbVie, Amgen, Pfizer
      • Speaker: AbbVie, Amgen, Lilly, Pfizer
      • Ownership interest: AbbVie, Amgen, Johnson & Johnson, Pfizer, Regeneron

  • Target Audience

    The primary target audiences are dermatologists and nurse practitioners and physician assistants who specialize in dermatology. Rheumatology providers and other clinicians who treat patients with psoriasis or PsA may benefit from participation in this activity.

  • Learning Objectives

    As a result of participation in this activity, participants should increase their ability to:

    1. Apply evidence-based clinical practice guideline recommendations to improve management of psoriatic disease and treatment outcomes.
    2. Summarize the results of key clinical trials for novel and emerging therapies intended to improve symptoms, and slow or prevent progression of psoriasis and PsA.
    3. Optimize individual treatment plans for psoriatic disease in the context of patient-provider shared decision making.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty, and do not necessarily reflect the views or recommendations of Forefront Collaborative and AbbVie.

    The content of this activity was independently peer reviewed by two reviewers and a patient with psoriasis and psoriatic arthritis. The reviewers of this activity had no relevant financial relationships to disclose.

    This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational grant from AbbVie. For further information concerning AbbVie grant funding, visit www.abbvie.com/grants

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule7 Dec 2022